1
|
Yang Y, Huang Z, Yuan M, Rui J, Chen R, Jin T, Sun Y, Deng Z, Shan H, Niu X, Liu W. Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma. Sci Rep 2023; 13:20914. [PMID: 38017005 PMCID: PMC10684554 DOI: 10.1038/s41598-023-46857-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 11/06/2023] [Indexed: 11/30/2023] Open
Abstract
Osteosarcoma is a heterogeneous disease with regard to its chemotherapy response and clinical outcomes. This study aims to investigate the genomic and transcriptomic characteristics related to pre-operative chemotherapy response. Samples from 25 osteosarcoma patients were collected to perform both whole exome and transcriptome sequencing. Osteosarcoma had significant amount of chromosomal copy number variants (CNVs). Chemotherapy responders showed the higher chromosomal CNV burden than non-responders (p = 0.0775), but the difference was not significant. The percentage of COSMIC signature 3, associated with homologous recombination repair deficiency, was higher in responders (56%) than in non-responders (45%). Transcriptomic analysis suggested that 11 genes were significantly up-regulated in responders and 18 genes were up-regulated in non-responders. Both GSEA and KEGG enrichment analysis indicted that four pathways related to cardiomyopathy were up-regulated in responders, while neuroactive ligand - receptor interaction was up-regulated in non-responders. Finally, a previously published chemoresistant model was validated using our dataset, with the area under the curve of 0.796 (95% CI, 0.583-1.000). Osteosarcoma had the heterogeneous mutational profile with frequent occurrence of CNVs. Transcriptomic analysis identified several signaling pathways associated with chemotherapy responsiveness to osteosarcoma. Transcriptomic signatures provides a potential research direction for predicting the chemotherapy response.
Collapse
Affiliation(s)
- Yongkun Yang
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China
- Fourth Medical College of Peking University, Beijing, 100035, China
| | - Zhen Huang
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China
- Fourth Medical College of Peking University, Beijing, 100035, China
| | | | - Jinqiu Rui
- Geneplus-Beijing, Beijing, 102206, China
| | | | - Tao Jin
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China
- Fourth Medical College of Peking University, Beijing, 100035, China
| | - Yang Sun
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China
- Fourth Medical College of Peking University, Beijing, 100035, China
| | - Zhiping Deng
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China
- Fourth Medical College of Peking University, Beijing, 100035, China
| | - Huachao Shan
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China
- Fourth Medical College of Peking University, Beijing, 100035, China
| | - Xiaohui Niu
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China
- Fourth Medical College of Peking University, Beijing, 100035, China
| | - Weifeng Liu
- Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing, 100035, China.
- Fourth Medical College of Peking University, Beijing, 100035, China.
| |
Collapse
|
2
|
Roessner A, Lohmann C, Jechorek D. Translational cell biology of highly malignant osteosarcoma. Pathol Int 2021; 71:291-303. [PMID: 33631032 DOI: 10.1111/pin.13080] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Accepted: 01/31/2021] [Indexed: 12/19/2022]
Abstract
Highly malignant osteosarcoma (HMO) is the most frequent malignant bone tumor preferentially occurring in adolescents and children with a second more flat peak in patients over the age of 60. The younger patients benefit from combined neoadjuvant chemotherapy with 65-70% 5-year survival rate. In patients with metastatic HMO the 5-year survival rate is consistently poor with approximately 30%. In the last several years strategies for target therapies have been developed by using next generation sequencing (NGS) for defining targetable molecular factors. However, it has so far been challenging to establish an effective target therapy for so-called 'orphan tumors' without recognizable driver mutations, including HMO. The molecular genetic studies using NGS have shown that HMOs are genomically unstable tumors with highly complex chaotic karyotypes. Before the background of this genetic complexity more investigations should be performed in the future for defining targetable biological factors. As the prognosis could not be improved for 40 years one may expect improvements for patients only by gaining a deeper understanding of the cell and molecular biology of HMO. The cell of origin of HMO is being clarified now. The majority of studies indicate that an osteoblastic progenitor cell is probably the cell of origin of HMO and not an undifferentiated mesenchymal stem cell. This means that the established histopathological definition of HMO through verification of osteoid production by the osteoblastic cells is well justified and will probably be the cornerstone for a precise differential diagnosis of HMO also in the years to come.
Collapse
Affiliation(s)
- Albert Roessner
- Department of Pathology, Otto-von-Guericke University, Magdeburg, Germany
| | - Christoph Lohmann
- Department of Orthopedics, Otto-von-Guericke University, Magdeburg, Germany
| | - Doerthe Jechorek
- Department of Pathology, Otto-von-Guericke University, Magdeburg, Germany
| |
Collapse
|
3
|
Monofunctional Platinum(II) Anticancer Agents. Pharmaceuticals (Basel) 2021; 14:ph14020133. [PMID: 33562293 PMCID: PMC7915149 DOI: 10.3390/ph14020133] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 02/02/2021] [Accepted: 02/04/2021] [Indexed: 12/15/2022] Open
Abstract
Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]+ (A: Ammonia or amine) stand out as a class of "non-traditional" anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.
Collapse
|
4
|
[Osteoid-forming bone tumors : Morphology and current translational cell biology]. DER PATHOLOGE 2020; 41:123-133. [PMID: 32078700 DOI: 10.1007/s00292-020-00763-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Osteoid osteoma and osteoblastoma are the most important benign osteoid-forming tumors. They grow slowly and are well differentiated. Histologically, the tumor cells show no atypia and no increased mitoses. In typical cases, they can be clearly diagnosed. However, the rare cases on the dividing line between osteoblastoma and osteosarcoma are extremely problematic. In these cases, molecular genetic investigations should contribute to finding the correct diagnosis in the future.Juvenile highly malignant osteosarcoma is the most important malignant osteoid-forming tumor. About 40 years ago, neoadjuvant chemotherapy was introduced for the mostly young patients. This therapy highly significantly improved prognosis. However, a plateau phase was quickly reached and the last several decades have seen no further progress in conventional therapeutic approaches. There is no doubt that further progress can only be achieved on the basis of new molecular genetic and cell biological findings. The target-therapeutic strategies derived from these findings will be discussed in this review.The rare parosteal osteosarcoma and the even rarer periosteal osteosarcoma are mostly not highly malignant tumors that are located on the surface of bone. The parosteal osteosarcoma is usually G1 and the periosteal osteosarcoma G2. Occasionally, the differential diagnosis between a parosteal osteosarcoma and a fibrous dysplasia is difficult. In such rare cases, the detection of GNAS mutations in fibrous dysplasia can prove useful. In contrast to chondromas and chondrosarcomas, periosteal osteosarcomas do not contain IDH1 and IDH2 mutations.
Collapse
|
5
|
Su QH, Xu XQ, Wang JF, Luan JW, Ren X, Huang HY, Bian SS. Anticancer Effects of Constituents of Herbs Targeting Osteosarcoma. Chin J Integr Med 2019; 25:948-955. [PMID: 31161441 DOI: 10.1007/s11655-019-2941-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/26/2018] [Indexed: 01/04/2023]
Abstract
Osteosarcoma is a rare primary malignancy of bone that is prone to early metastasis. Resection surgery and chemotherapeutic regimens are current standard treatments for osteosarcoma. However, the long-term survival rate of patients with osteosarcoma is low due to a high risk of metastasis. Hence, a new approach is urgently needed to improve the treatment of osteosarcoma. Compared with chemotherapy, natural active constituents isolated from herbs exhibit less adverse effects and better anti-tumor effects. This study aimed to summarize the anticancer effects of constituents of herbs on the progression and metastasis of osteosarcoma cells. It showed that many constituents of herbs inhibited osteosarcoma by targeting proliferation, matrix metalloproteinases, integrin and cadherin, and angiogenesis. The findings might be beneficial for the development of new drugs and treatment strategies.
Collapse
Affiliation(s)
- Qing-Hong Su
- Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, 250062, China
| | - Xiao-Qun Xu
- Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, 250062, China
| | - Jun-Fu Wang
- Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, 250062, China
| | - Jun-Wen Luan
- Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, 250062, China
| | - Xia Ren
- Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, 250062, China
| | - Hai-Yan Huang
- Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, 250062, China
| | - Si-Shan Bian
- Department of Orthopaedics, the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
| |
Collapse
|
6
|
Ye M, Misra SK, De AK, Ostadhossein F, Singh K, Rund L, Schook L, Pan D. Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma. J Med Chem 2018; 61:10739-10752. [PMID: 30375864 DOI: 10.1021/acs.jmedchem.8b01387] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin. Their genetic heterogeneity coupled with uncertain histogenesis makes them difficult to treat and results in poor prognosis. In this work, we show that structure-based drug discovery involving computational modeling can be used to identify a new retinoid X receptor (RXR) agonist ligand with a bis(indolyl)methane scaffold. This agent co-self-assembles with an amphiphilic diblock copolymer resulting in nanoparticles (Nano-RXR) with excellent kinetic stability, which were evaluated for efficacy and safety in transformed sarcoma cells, 63-3 Cre and 141-10 Cre of pig origin, and in rodent xenograft models. Responses at gene and protein levels established the treatment approach as a highly effective RXR agonist across cell, rodent, and "Oncopig" models. Interestingly, Nano-RXR was not only able to modulate metabolic and transporter genes related to orphan nuclear receptors but also played a major role in modulating programmed cell death in sarcomas developed in Oncopigs.
Collapse
Affiliation(s)
- Mao Ye
- Department of Bioengineering , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Santosh K Misra
- Department of Bioengineering , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Arun K De
- Department of Animal Sciences , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Agricultural Animal Care and Use Program , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Fatemeh Ostadhossein
- Department of Bioengineering , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Kuldeep Singh
- Veterinary Diagnostic Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Laurie Rund
- Department of Animal Sciences , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Agricultural Animal Care and Use Program , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Veterinary Diagnostic Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Lawrence Schook
- Department of Animal Sciences , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Agricultural Animal Care and Use Program , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Veterinary Diagnostic Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Dipanjan Pan
- Department of Bioengineering , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Beckman Institute of Advanced Science and Technology , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Mills Breast Cancer Institute , Carle Foundation Hospital , 502 N. Busey , Urbana , Illinois 61801 , United States.,Department of Materials Science and Engineering , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States.,Carle-Illinois College of Medicine , Urbana , Illinois 61801 , United States
| |
Collapse
|
7
|
Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism. Proc Natl Acad Sci U S A 2018; 115:E11128-E11137. [PMID: 30385632 DOI: 10.1073/pnas.1814044115] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Osteosarcoma (OS), the most common primary bone tumor, is highly metastatic with high chemotherapeutic resistance and poor survival rates. Using induced pluripotent stem cells (iPSCs) generated from Li-Fraumeni syndrome (LFS) patients, we investigate an oncogenic role of secreted frizzled-related protein 2 (SFRP2) in p53 mutation-associated OS development. Interestingly, we find that high SFRP2 expression in OS patient samples correlates with poor survival. Systems-level analyses identified that expression of SFRP2 increases during LFS OS development and can induce angiogenesis. Ectopic SFRP2 overexpression in normal osteoblast precursors is sufficient to suppress normal osteoblast differentiation and to promote OS phenotypes through induction of oncogenic molecules such as FOXM1 and CYR61 in a β-catenin-independent manner. Conversely, inhibition of SFRP2, FOXM1, or CYR61 represses the tumorigenic potential. In summary, these findings demonstrate the oncogenic role of SFRP2 in the development of p53 mutation-associated OS and that inhibition of SFRP2 is a potential therapeutic strategy.
Collapse
|
8
|
Xu H, Zhu X, Bao H, Wh Shek T, Huang Z, Wang Y, Wu X, Wu Y, Chang Z, Wu S, Tang Q, Zhang H, Han A, Mc Cheung K, Zou C, Yau R, Ho WY, Huang G, Batalha S, Lu J, Song G, Kang Y, Shao YW, Lam YL, Shen J, Wang J. Genetic and clonal dissection of osteosarcoma progression and lung metastasis. Int J Cancer 2018; 143:1134-1142. [PMID: 29569716 DOI: 10.1002/ijc.31389] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 02/09/2018] [Accepted: 02/21/2018] [Indexed: 01/05/2023]
Affiliation(s)
- Huaiyuan Xu
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
- Department of Musculoskeletal Oncology; Sun Yat-Sen University Cancer Center; Guangzhou Guangdong China
| | - Xiaojun Zhu
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
| | - Hua Bao
- Translational Medicine Research Institute, Geneseeq Technology Inc.; Toronto Ontario Canada
| | - Tony Wh Shek
- Department of Pathology; University of Hong Kong, Queen Mary Hospital; Hong Kong China
| | - Zongwen Huang
- Department of Orthopaedics; the Fifth Affiliated Hospital of Sun Yat-Sen University; Zhuhai China
| | - Yongqian Wang
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
| | - Xue Wu
- Translational Medicine Research Institute, Geneseeq Technology Inc.; Toronto Ontario Canada
| | - Yong Wu
- Nanjing Geneseeq Technology Inc.; Nanjing Jiangsu China
| | - Zhili Chang
- Nanjing Geneseeq Technology Inc.; Nanjing Jiangsu China
| | - Shuyu Wu
- Nanjing Geneseeq Technology Inc.; Nanjing Jiangsu China
| | - Qinglian Tang
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
- Department of Musculoskeletal Oncology; Sun Yat-Sen University Cancer Center; Guangzhou Guangdong China
| | - Huizhong Zhang
- Department of Pathology; Sun Yat-Sen University Cancer Center; Guangzhou China
| | - Anjia Han
- Department of Pathology; the first Affiliated Hospital, Sun Yat-Sen University; Guangzhou China
| | - Kenneth Mc Cheung
- Department of Orthopaedics and Traumatology; University of Hong Kong, Queen Mary Hospital; Hong Kong China
| | - Changye Zou
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
| | - Raymond Yau
- Department of Orthopaedics and Traumatology; University of Hong Kong, Queen Mary Hospital; Hong Kong China
| | - Wai-Yip Ho
- Department of Orthopaedics and Traumatology; University of Hong Kong, Queen Mary Hospital; Hong Kong China
| | - Gang Huang
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
| | - Sellma Batalha
- Department of Anatomic Pathology; Centro Hospitalar Conde de Sao Januario; Macau China
| | - Jinchang Lu
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
| | - Guohui Song
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
- Department of Musculoskeletal Oncology; Sun Yat-Sen University Cancer Center; Guangzhou Guangdong China
| | - Yao Kang
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
| | - Yang W. Shao
- Translational Medicine Research Institute, Geneseeq Technology Inc.; Toronto Ontario Canada
- School of Public Health; Nanjing Medical University; Nanjing Jiangsu China
| | - Ying Lee Lam
- Department of Orthopaedics and Traumatology; University of Hong Kong, Queen Mary Hospital; Hong Kong China
| | - Jingnan Shen
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
| | - Jin Wang
- Department of Musculoskeletal Oncology; the First Affiliated Hospital of Sun Yat-Sen University; Guangzhou Guangdong China
- Department of Musculoskeletal Oncology; Sun Yat-Sen University Cancer Center; Guangzhou Guangdong China
| |
Collapse
|
9
|
Zhang Z, Zhu Z, Luo C, Zhu C, Zhang C, Guo Z, Wang X. A Potential Bone-Targeting Hypotoxic Platinum(II) Complex with an Unusual Cytostatic Mechanism toward Osteosarcoma Cells. Inorg Chem 2018. [PMID: 29513007 DOI: 10.1021/acs.inorgchem.7b03261] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Osteosarcoma (OS) is the most common primary pediatric bone tumor lethal to children and adolescents. Chemotherapeutic agents such as cisplatin are not effective for OS because of their poor accessibility to this cancer and severe systemic toxicity. In this study, a lipophilic platinum(II) complex bearing a bisphosphonate bone-targeting moiety, cis-[PtL(NH3)2Cl]NO3 {BPP; L = tetraethyl [2-(pyridin-2-yl)ethane-1,1-diyl]bisphosphonate}, was prepared and characterized by NMR, electrospray ionization mass spectrometry, and single-crystal X-ray crystallography. The cytotoxicity of BPP toward OS cell lines U2OS and MG-63 was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. BPP exhibits moderate inhibition against U2OS cells through a mechanism involving both DNA binding and a mevalonate pathway. The acute toxicity of BPP to mice is 7-fold lower than that of cisplatin. The relative low systemic toxicity may result from the steric hindrance of the ligand, which blocks BPP approaching the bases of DNA. The results suggest that incorporating bisphosphonates into a platinum complex not only enhances its bone-targeting property but also minimizes its reactivity toward DNA and thereby lowers the systematic toxicity of the complex. The diminished cytotoxicity of BPP could be compensated for by increasing the therapeutic dose with marginal harm. This strategy provides a new possibility for overcoming the ineffectiveness and systemic toxicity of platinum drugs in the treatment of OS.
Collapse
Affiliation(s)
- Zhenqin Zhang
- School of Pharmacy , Nanjing Medical University , Nanjing 211166 , People's Republic of China
| | | | | | | | | | | | | |
Collapse
|
10
|
Chiappetta C, Mancini M, Lessi F, Aretini P, De Gregorio V, Puggioni C, Carletti R, Petrozza V, Civita P, Franceschi S, Naccarato AG, Rocca CD, Mazzanti CM, Di Cristofano C. Whole-exome analysis in osteosarcoma to identify a personalized therapy. Oncotarget 2017; 8:80416-80428. [PMID: 29113313 PMCID: PMC5655208 DOI: 10.18632/oncotarget.19010] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 06/20/2017] [Indexed: 11/25/2022] Open
Abstract
Osteosarcoma is the most common pediatric primary non-hematopoietic bone tumor. Survival of these young patients is related to the response to chemotherapy and development of metastases. Despite many advances in cancer research, chemotherapy regimens for osteosarcoma are still based on non-selective cytotoxic drugs. It is essential to investigate new specific molecular therapies for osteosarcoma to increase the survival rate of these patients. We performed exomic sequence analyses of 8 diagnostic biopsies of patients with conventional high grade osteosarcoma to advance our understanding of their genetic underpinnings and to correlate the genetic alteration with the clinical and pathological features of each patient to identify a personalized therapy. We identified 18,275 somatic variations in 8,247 genes and we found three mutated genes in 7/8 (87%) samples (KIF1B, NEB and KMT2C). KMT2C showed the highest number of variations; it is an important component of a histone H3 lysine 4 methyltransferase complex and it is one of the histone modifiers previously implicated in carcinogenesis, never studied in osteosarcoma. Moreover, we found a group of 15 genes that showed variations only in patients that did not respond to therapy and developed metastasis and some of these genes are involved in carcinogenesis and tumor progression in other tumors. These data could offer the opportunity to get a key molecular target to identify possible new strategies for early diagnosis and new therapeutic approaches for osteosarcoma and to provide a tailored treatment for each patient based on their genetic profile.
Collapse
Affiliation(s)
- Caterina Chiappetta
- UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Latina, Italy
| | - Massimiliano Mancini
- UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Latina, Italy
| | | | | | | | - Chiara Puggioni
- UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Latina, Italy
| | - Raffaella Carletti
- UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Latina, Italy
| | - Vincenzo Petrozza
- UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Latina, Italy
| | | | | | | | - Carlo Della Rocca
- UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Latina, Italy
| | | | - Claudio Di Cristofano
- UOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Latina, Italy
| |
Collapse
|
11
|
Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death Dis 2016; 7:e2389. [PMID: 27685633 PMCID: PMC5059871 DOI: 10.1038/cddis.2016.272] [Citation(s) in RCA: 116] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Revised: 07/27/2016] [Accepted: 08/01/2016] [Indexed: 01/01/2023]
Abstract
Long noncoding RNAs (lncRNAs) are a class of non-protein-coding molecules longer than 200 nucleotides that are involved in the development and progression of many types of tumors. Numerous lncRNAs regulate cell proliferation, metastasis, and chemotherapeutic drug resistance. Osteosarcoma is one of the main bone tumor subtypes that poses a serious threat to adolescent health. We summarized how lncRNAs regulate osteosarcoma progression, invasion, and drug resistance, as well as how lncRNAs can function as biomarkers or independent prognostic indicators with respect to osteosarcoma therapy.
Collapse
|
12
|
Wang L, Kang FB, Sun N, Wang J, Chen W, Li D, Shan BE. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma. Tumour Biol 2016; 37:14939-14947. [PMID: 27644254 DOI: 10.1007/s13277-016-5386-2] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Accepted: 09/09/2016] [Indexed: 12/11/2022] Open
Abstract
Our previous studies have shown that the expression level of B7 homolog 3 (B7-H3) was correlated with clinical staging and prognosis of osteosarcoma (OS) patients, and its silencing inhibited the proliferation and invasion of OS cells in vitro. However, its overexpression mechanism behind was far from elucidated. On the basis of bioinformatics and the preliminary screening data, we hypothesized that miR-124 might play an important role in OS development and as a lead candidate for modulating B7-H3 expression. In this study, we found that miR-124 was downregulated significantly in OS tumor tissue, compared to normal adjacent tissues (NATs). Lower miR-124 expression levels were associated with advanced Ennecking stage, lower tumor differentiation, and common pulmonary metastasis. The 5-year overall survival rate in the miR-124 upregulated group was 61.5 %, while with low miR-124 expression, only 11.8 % survived. Further studies in vitro showed that B7-H3 was a direct target of miR-124. Overexpression of miR-124 decreased B7-H3 mRNA and protein level and inhibited B7-H3 3'-UTR reporter activity. Treatment of OS cells with miR-124 mimics induced the inhibition of cell growth and invasion in vitro, which could be abrogated by transfected by B7-H3 expression vector. Our findings highlight the potential application of miR-124 as a novel onco-miRNA in OS, and its oncogenic effects are mediated chiefly through downregulation of B7-H3, thus suggesting a model for identifying miR-124 that can be exploited to improve the therapeutic potential efficacy of mAb targeting to B7-H3.
Collapse
Affiliation(s)
- Ling Wang
- Cancer Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.,Department of Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Fu-Biao Kang
- Department of Liver Diseases, Bethune International Peace Hospital, Shijiazhuang, Hebei, People's Republic of China
| | - Nan Sun
- Blood transfusion division, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China
| | - Juan Wang
- Department of Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Wei Chen
- Department of Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
| | - Dong Li
- Department of Liver Diseases, Bethune International Peace Hospital, Shijiazhuang, Hebei, People's Republic of China
| | - Bao-En Shan
- Cancer Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
| |
Collapse
|